Walgreen profit falls; flu season may help this quarter
(Reuters) - Walgreen Co (WAG.N) posted an unexpected decline in quarterly profit on Friday as the largest U.S. drugstore chain worked on winning back former customers and changed how it accounts for its first international acquisition.
The company stands to get a bit of a sales lift in the current quarter as a strong flu season brings shoppers in for flu shots and medications.
Walgreen lost millions of customers due to a contract dispute with pharmacy benefits manager Express Scripts Holding Co (ESRX.O) and is trying to lure them back with offers such as $25 gift cards. It is seeing an increasing pace of Express Scripts patients returning to its stores.
Earnings in the latest quarter were hurt by a decision to report results from Walgreen's stake in Europe's Alliance Boots Holding Ltd ABN.UL on a one-quarter lag rather than a one-month lag. The decision was based on regulatory, audit and business concerns, the company said.
Shares of Walgreen, which has 8,000 U.S. drugstores, fell 3.75 percent to $36.14 in midday trading.
"It was messy," Gabelli & Co research analyst Jeff Jonas said of the quarterly results, noting they included items such as the change in reporting results from Alliance Boots as well as a charge for costs stemming from Hurricane Sandy.
"If you give them credit for everything, it was actually a good quarter," he said.
FLU UP, PROFIT DOWN
The Centers For Disease Control is projecting the worst flu season in 10 years, and Walgreen has seen strong demand for flu shots and other immunizations continue into December, Chief Executive Greg Wasson said.
Through the end of its fiscal first quarter on November 30, Walgreen had given more than 5 million flu shots, up from a year earlier. It has also seen sales of cough and cold medications pick up.
A strong flu season should help the industry in December and likely for the next couple of months, said Jonas.
Walgreen earned $413 million, or 43 cents per share, in the first quarter, down from $554 million, or 63 cents per share, a year earlier.
Earnings before unusual items fell to 58 cents per share from 71 cents a year earlier, missing analysts' average forecast of 70 cents, according to Thomson Reuters I/B/E/S.
Unusual items in the latest quarter included costs related to acquisitions, an inventory provision, and the effects of Hurricane Sandy.
Results from Alliance Boots cut adjusted earnings per share by 7 cents, rather than adding 3 cents as was expected if results had been reported using a one-month lag.
Walgreen paid $7 billion in cash and stock for a 45 percent stake in the European pharmacy operator in August and has an option to buy the rest of the company in about three years.
Walgreen's first-quarter sales fell 4.6 percent to $17.32 billion, with sales at stores open at least a year, or same-store sales, down 8 percent.
The sales performance was slightly worse than Walgreen reported earlier this month. At that time, it said sales fell 4.5 percent to $17.34 billion and same-store sales declined 7.7 percent.
Since settling its dispute with Express Scripts, Walgreen has stepped up its marketing to bring back Express Scripts patients and also has been promoting a new loyalty card, signing up more than 45 million shoppers in a few months.
Rivals CVS Caremark Corp (CVS.N) and Rite Aid Corp (RAD.N) are trying to hold onto the customers they gained when Walgreen lost its Express Scripts patients.
On December 13, CVS said it still expected to retain at least 60 percent of the Walgreen patrons that switched to its chain, which should boost CVS' fourth-quarter earnings by at least 12.5 cents per share.
On Thursday, Rite Aid said it has retained "the lion's share" of patients it gained during the dispute.
(Reporting by Jessica Wohl in Chicago; Editing by Jeffrey Benkoe and John Wallace)
- Target confirms major card data theft during Thanksgiving
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- As Modi storms into India's election, a quiet alternative emerges
- U.S. prosecutor defends treatment of Indian diplomat |